We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics


PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App

High-Capacity Serological Assay Developed for Celiac Disease

By LabMedica International staff writers
Posted on 02 Sep 2022
Print article
Image: The AutoDELFIA 1235 is an automatic immunoassay system (Photo courtesy of PerkinElmer Life Sciences)
Image: The AutoDELFIA 1235 is an automatic immunoassay system (Photo courtesy of PerkinElmer Life Sciences)

Celiac disease is a chronic inflammatory disorder of the small intestinal mucosa occurring in genetically predisposed individuals exposed to dietary gluten proteins of wheat (gliadin and glutenin), barley (hordein) or rye (secalin) origin.

Currently, in adult patients a diagnosis of celiac disease is usually made through a combination of serological testing and endoscopic biopsy. A common approach is to screen for serum IgA antibodies to transglutaminase 2 (anti-TG2 IgA) and IgG antibodies to deamidated gliadin peptides (anti-DGP IgG). The diagnosis is confirmed by histological examination of the small intestinal mucosa.

Medical Biochemists at the Oslo University Hospital (Oslo, Norway) and their international colleagues developed and clinically validated a high-throughput assay for serum IgA and IgG antibodies against transglutaminase-2 (TG2) and determined appropriate assay cut-offs for large-scale population screening for celiac disease. They screened 1,920 individuals from the general population.

The assay protocol was automated on the AutoDELFIA 1235 automated immunoassay platform (PerkinElmer Life Sciences, Oslo, Norway). Total serum IgA was also measured using the Alinity Immunoglobulin A (Abbott Diagnostics, Oslo, Norway) at the time of endoscopy in order to determine if individuals classified as anti-TG2 IgG-responders had lower levels of total IgA when compared to anti-TG2 IgA responders. Subjects with serum anti-TG2 concentrations above a preliminary cut-off (>0.3 mg*/L anti-TG2 IgA or >0.5 mg*/L anti-TG2 IgG) were offered endoscopic examination and biopsy. A diagnosis of celiac disease was given if villous atrophy (Marsh grade 3) was found.

The investigators reported that the assay had a limit of quantification of 0.25 mg*/L (anti-TG2 IgA) and 0.60 mg*/L (anti-TG2 IgG) with imprecision (CV) < 16% and <18% respectively. A total of 66 individuals were above the preliminary cut-off, and 56 underwent endoscopy. Of these, 26 were diagnosed with celiac disease. The team reported that 68% of subjects with anti-TG2 IgA ≥ 0.7 mg*/L or anti-TG2 IgG ≥ 1.0 mg*/L had biopsy-proven celiac disease, and utilization of these higher cut-offs identified 96% of biopsy-positive patients. At the time of endoscopy, all individuals with anti-TG2 IgA > 2.0 mg*/L had celiac disease, and this cut-off identified 88% of newly diagnosed celiac patients and 8% (2/26) of the newly diagnosed patients had primarily anti-TG2 IgG.

The authors concluded that their study described a robust, high-capacity and fully automated assay with excellent performance suitable for celiac disease screening in the general population. The study was published on August 9, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Oslo University Hospital 
PerkinElmer Life Sciences 
Abbott Diagnostics 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.